mrtx1719
Small moleculeexperimental
Clinical trial activity
8 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
3
Phase 3
2
Phase 4
0
Earliest trial started Jun 2, 2022 (NCT05245500)
Timeline
Indications
Mechanism of action
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07283705 | Phase 2 | May 18, 2026 | Bristol-Myers Squibb, University of Texas at Houston |
| NCT07063745 | Phase 2/Phase 3 (Phase 3) | Nov 28, 2025 | Bristol-Myers Squibb |
| NCT07076121 | Phase 2/Phase 3 (Phase 3) | Oct 23, 2025 | Bristol-Myers Squibb |
| NCT07077434 | Phase 1 | Oct 15, 2025 | Bristol-Myers Squibb |
| NCT06855771 | Phase 2 | May 30, 2025 | Bristol-Myers Squibb |
| NCT06883747 | Early Phase 1 (Phase 1) | Apr 28, 2025 | Ivy Brain Tumor Center, University of Arizona |
| NCT06672523 | Phase 1 | Dec 16, 2024 | Bristol-Myers Squibb |
| NCT05245500 | Phase 1/Phase 2 (Phase 2) | Jun 2, 2022 | Mirati Therapeutics Inc. |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bristol-Myers Squibb | For profit | 6 | 5 | 3 | 2024 |
| Ivy Brain Tumor Center | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Mirati Therapeutics Inc. | For profit | 1 | 1 | 1 | 2022 |
| University of Arizona | Academic/Hospital | 1 | 1 | 1 | 2025 |
| University of Texas at Houston | Academic/Hospital | 1 | 1 | 1 | 2026 |
5 organizations
Page 1 / 1